2-(1-Hydroxypropoxy)butan-1-ol

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(1-Hydroxypropoxy)butan-1-ol
• 英文别名: 2-(1-hydroxypropoxy)butan-1-ol
• 化学式: C₇H₁₆O₃
• 分子量: 148.2
• InChiKey: POXWLBNDLPVZKE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] AURISTATIN COMPOUNDS AND CONJUGATES THEREOF<br/>[FR] COMPOSÉS AURISTATINE ET LEURS CONJUGUÉS
  申请人：MERSANA THERAPEUTICS INC

  公开号：WO2014093379A1

  公开（公告）日：2014-06-19

  An auristatin compound conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -LD- D, the protein based recognition-molecule being connected to the polymeric carrier by Lp. Each occurrence of D is independently an auristatin compound having a molecular weight ≤ 5 kDa. LD and Lp are distinct linkers connecting the auristatin compound and PBRM to the polymeric earner respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-auristatin compound-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.

  本文提供了一种auristatin化合物结合物。该结合物包括基于蛋白质的识别分子（PBRM）和聚合物载体，其被取代一个或多个-LD-D，其中，基于蛋白质的识别分子通过Lp与聚合物载体相连。每个D的出现都是独立的，具有分子量≤5 kDa的auristatin化合物。LD和Lp是连接auristatin化合物和PBRM到聚合物载体的不同连接物。还揭示了用于与PBRM结合形成聚合物-auristatin化合物-PBRM结合物的聚合物支架，以及包括结合物的组合物，其制备方法以及使用结合物或其组合物治疗各种疾病的方法。
• PROTEIN-POLYMER-DRUG CONJUGATES
  申请人：MERSANA THERAPEUTICS, INC.

  公开号：US20150044160A1

  公开（公告）日：2015-02-12

  A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -L D -D, the protein based recognition-molecule being connected to the polymeric carrier by L P . Each occurrence of D is independently a therapeutic agent having a molecular weight ≦5 kDa. L D and L P are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.

  本文提供一种药物偶联物。该偶联物包括一种基于蛋白质的识别分子（PBRM）和一种聚合物载体，其取代了一个或多个-LD-D，其中，基于蛋白质的识别分子通过LP连接到聚合物载体上。每个D的出现都是独立的，其分子量≦5 kDa，是一种治疗剂。LD和LP是连接治疗剂和PBRM到聚合物载体的连接体。还公开了用于与PBRM偶联形成聚合物-药物-PBRM偶联物的聚合物支架，包括所述偶联物的组合物，其制备方法以及使用偶联物或其组合物治疗各种疾病的方法。
• US8808679B2
  申请人：——

  公开号：US8808679B2

  公开（公告）日：2014-08-19
• US9144615B2
  申请人：——

  公开号：US9144615B2

  公开（公告）日：2015-09-29
• [EN] PROTEIN-POLYMER-DRUG CONJUGATES AND METHODS OF USING SAME<br/>[FR] CONJUGUÉS MÉDICAMENT-PROTÉINE-POLYMÈRE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：MERSANA THERAPEUTICS INC

  公开号：WO2015195925A1

  公开（公告）日：2015-12-23

  A polymeric scaffold useful for conjugating with a protein based recognition-molecule (PBRM) to form a PBRM-polymer-drug conjugate is described herein. The scaffold includes one or more terminal maleimido groups. Also disclosed is a PBRM-polymer-drug conjugate prepared from the scaffold. Compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders, such as cancer in a subject having low HER2 expression with the conjugates or their compositions are also described.